ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2141

Glucocorticoid Therapy-Associated Bone Fractures Are Associated with Osteoporosis Underscreening in Patients with Rheumatoid Arthritis
Abstract Number: 2142

Comparison of Bone Mineral Density at the Distal Radius, Hip, and Lumbar Spine in Female Patients Undergoing Surgery for Proximal Femur or Distal Radius Fractures: Implications for Osteoporosis Diagnosis
Abstract Number: 2143

Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Abstract Number: 2144

Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Abstract Number: 2145

Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.
Abstract Number: 2146

Validation of the Simple Calculated Osteoporosis Risk Estimation and Osteoporosis Self-assessment Tool Among People Aging with HIV in Peru
Abstract Number: 2147

Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients
Abstract Number: 2148

Impact of Hip Fractures in the Elderly Population: Functional Status, Readmission, and One-Year Mortality
Abstract Number: 2149

Rheumatoid Arthritis: Patient’s Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study
Abstract Number: 2150

Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Abstract Number: 2151

Rheumatology on Reddit: A Descriptive Analysis
Abstract Number: 2152

Factors Associated with Health-related Quality of Life in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – a Cross Sectional Analysis from the SAPHO-CNO Study
Abstract Number: 2153

Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Abstract Number: 2154

“I Have Taken Five Different Kinds of Tablets and Injections, and I Still Have Foot Pain”: An International Outcome Measures in Rheumatology (OMERACT) Qualitative Study Exploring Patient Perspectives of Foot and Ankle Disorders
Abstract Number: 2155

Direct Comparison of Sleep Quality and Risk Factors for Poor Sleep Across Rheumatoid Arthritis, Axial Spondyloarthritis and Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].